Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Toxicology
Published in: Cardiovascular Toxicology 10-11/2022

Open Access 15-10-2022 | Dapagliflozin

RETRACTED ARTICLE: Dapagliflozin Guards Against Cadmium-Induced Cardiotoxicity via Modulation of IL6/STAT3 and TLR2/TNFα Signaling Pathways

Authors: Marwa M. M. Refaie, Rehab Ahmed Rifaai, Michael Atef Fawzy, Sayed Shehata

Published in: Cardiovascular Toxicology | Issue 10-11/2022

Login to get access

Abstract

Cadmium (Cd) is a common environmental pollutant that leads to severe cardiotoxic hazards. Several studies were carried out to protect the myocardium against Cd-induced cardiotoxicity. Up till now, no researches evaluated the protective effect of dapagliflozin (DAP) against Cd induced cardiotoxicity. Thus, we aimed to explore the role of DAP in such model with deep studying of the involved mechanisms. 40 male Wistar albino rats were included in current study. Cd (5 mg/kg/day) was administered orally for 7 days to induce cardiotoxicity with or without co-administration of DAP in three different doses (2.5, 5, 10 mg/kg/day) orally for 7 days. Our data revealed that Cd could induce cardiotoxicity with significant increase in serum cardiac enzymes, heart weight, tissue malondialdehyde (MDA), tumor necrosis factor alpha (TNFα), nuclear factor kappa B (NFκB), toll like receptor2 (TLR2), interleukin 6 (IL6) and caspase3 immunoexpression with abnormal histopathological changes. In addition, Cd significantly decreased the level of heme oxygenase1 (HO1), nuclear factor erythroid 2-related factor 2 (Nrf2), signal transducer and activator of transcription (STAT3), reduced glutathione (GSH), glutathione peroxidase (GPx), and total antioxidant capacity (TAC). Co-administration of DAP could ameliorate Cd cardiotoxicity with significant improvement of the biochemical and histopathological changes. We found that DAP had protective properties against Cd induced cardiotoxicity and this may be due to its anti-oxidant, anti-inflammatory, anti-apoptotic properties and modulation of IL6/STAT3 and TLR2/TNFα-signaling pathways.
Appendix
Available only for authorised users
Literature
1.
Sarmiento-Ortega, V. E., Brambila, E., Flores-Hernández, J. Á., Díaz, A., Peña-Rosas, U., & Moroni-González, D. (2018). The NOAEL metformin dose is ineffective against metabolic disruption induced by chronic cadmium exposure in wistar rats. Toxics, 6(3), E55.CrossRef
2.
Refaie, M. M. M., El-Hussieny, M., Bayoumi, A. M. A., & Shehata, S. (2019). Mechanisms mediating the cardioprotective effect of carvedilol in cadmium induced cardiotoxicity. Role of eNOS and HO1/Nrf2 pathway. Environmental Toxicology Pharmacology, 70, 103198.PubMedCrossRef
3.
Chang, H., Zhao, F., Xie, X., et al. (2019). PPARα suppresses Th17 cell differentiation through IL-6/STAT3/RORγt pathway in experimental autoimmune myocarditis. Experimental Cell Research, 375(1), 22–30.PubMedCrossRef
4.
Shati, A. A., & El-Kott, A. F. (2019). Acylated ghrelin prevents doxorubicin-induced cardiac intrinsic cell death and fibrosis in rats by restoring IL-6/JAK2/STAT3 signaling pathway and inhibition of STAT1. Naunyn Schmiedebergs Arch Pharmacology, 392(9), 1151–1168.CrossRef
5.
6.
Heinrich, P. C., Behrmann, I., Haan, S., Hermanns, H. M., Müller-Newen, G., & Schaper, F. (2003). Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical Journal, 374(1), 1–20.PubMedPubMedCentralCrossRef
7.
Lee, T. M., Chang, N. C., & Lin, S. Z. (2017). Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radical Biology and Medicine, 104, 298–310.PubMedCrossRef
8.
Refaie, M. M. M., Shehata, S., Bayoumi, A. M. A., El-Tahawy, N. F. G., & Abdelzaher, W. Y. (2022). The IL-6/STAT signaling pathway and PPARα are involved in mediating the dose-dependent cardioprotective effects of fenofibrate in 5-fluorouracil-induced cardiotoxicity. Cardiovascular Drugs & Therapy., 36(5), 817–827.CrossRef
9.
El-Zayat, S. R., Sibaii, H., & Mannaa, F. A. (2019). Toll-like receptors activation, signaling, and targeting: An overview. Bulletin of the National Research Centre., 43(1), 187.CrossRef
10.
Arslan, F., Smeets, M. B., O’Neill, L. A., et al. (2010). Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation, 121(1), 80–90.PubMedCrossRef
11.
Cristofaro, P., & Opal, S. M. (2003). The Toll-like receptors and their role in septic shock. Expert Opinion on Therapeutic Targets, 7(5), 603–612.PubMedCrossRef
12.
Ehrentraut, H., Weber, C., Ehrentraut, S., et al. (2011). The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy. European Journal of Heart Failure, 13(6), 602–610.PubMedCrossRef
13.
14.
Abdel-Wahab, A. F., Bamagous, G. A., Al-Harizy, R. M., et al. (2018). Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. Biomedicine & Pharmacotherapy., 103, 59–66.CrossRef
15.
Tanajak, P., Sa-Nguanmoo, P., Sivasinprasasn, S., et al. (2018). Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. Journal of Endocrinololgy, 236(2), 69–84.CrossRef
16.
Erdogan, M. A., Yusuf, D., Christy, J., et al. (2018). Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy. BMC Neurology Journal, 18(1), 81.CrossRef
17.
Oguma, T., Nakayama, K., Kuriyama, C., et al. (2015). Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon-like peptide-1 secretion in normal and diabetic rodents. Journal of Pharmacology and Experimental Therapeutics, 354, 279–289.PubMedCrossRef
18.
Lahnwong, S., Palee, S., Apaijai, N., et al. (2020). Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. Cardiovascular Diabetology, 19(1), 91.PubMedPubMedCentralCrossRef
19.
Shin, S. J., Chung, S., Kim, S. J., et al. (2016). Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS ONE, 11(11), e0165703.PubMedPubMedCentralCrossRef
20.
Lahnwong, S., Chattipakorn, S. C., & Chattipakorn, N. (2018). Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors. Cardiovascular Diabetology, 17(10), 1.
21.
Joubert, M., Jagu, B., Montaigne, D., et al. (2017). The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes, 66(4), 1030–1040.PubMedCrossRef
22.
Jaikumkao, K., Pongchaidecha, A., Chueakula, N., et al. (2018). Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats. Diabetes, Obesity and Metabolism, 20(11), 2617–2626.PubMedCrossRef
23.
Mukherjee, R., Banerjee, S., Joshi, N., Singh, P. K., Baxi, D., & Ramachandran, A. V. (2011). A combination of melatonin and alpha lipoic acid has greater cardioprotective effect than either of them singly against cadmium-induced oxidative damage. Cardiovascular Toxicology, 11(1), 78–88.PubMedCrossRef
24.
Arab, H. H., Al-Shorbagy, M. Y., & Saad, M. A. (2021). Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK/mTOR, HMGB1/RAGE and Nrf2/HO-1 pathways. Chemico-Biological Interactions, 335, 109368.PubMedCrossRef
25.
Kingir, Z. B., Özdemir Kural, Z. N., Cam, M. E., et al. (2019). Effects of dapagliflozin in experimental sepsis model in rats. Ulus Travma Acil Cerrahi Derg, 25(3), 213–221.PubMed
26.
Buege, J. A., & Aust, S. D. (1978). Microsomal lipid peroxidation. Methods in Enzymology, 52, 302–310.PubMedCrossRef
27.
Moron, M. S., Depierre, J. W., & Mannervik, B. (1979). Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochimica et Biophysica Acta, 582(1), 67–78.PubMedCrossRef
28.
Chadha, S., Wang, L., Hancock, W. W., & Beier, U. H. (2019). Sirtuin-1 in immunotherapy: A Janus-headed target. Journal of Leukocyte Biology, 106(2), 337–343.PubMedCrossRef
29.
Chen, Y., Zhang, Y., Huo, Y., Wang, D., & Hong, Y. (2016). Adrenomedullin mediates tumor necrosis factor-alpha-induced responses in dorsal root ganglia in rats. Brain Research, 1644, 183–191.PubMedCrossRef
30.
Hamza, A. A., Fikry, E. M., Abdallah, W., & Amin, A. (2018). Mechanistic insights into the augmented effect of bone marrow mesenchymal stem cells and thiazolidinediones in streptozotocin-nicotinamide induced diabetic rat. Scientific Reports, 8(1), 9827.PubMedPubMedCentralCrossRef
31.
Milton Prabu, S., Muthumani, M., & Shagirtha, K. (2013). Quercetin potentially attenuates cadmium induced oxidative stress mediated cardiotoxicity and dyslipidemia in rats. European Review for Medical and Pharmacological Sciences, 17(5), 582–595.PubMed
32.
Nishiyama, S., Saito, N., Konishi, Y., Abe, Y., & Kusumi, K. (1990). Cardiotoxicity in magnesium-deficient rats fed cadmium. Journal of Nutritional Science and Vitaminology, 36(1), 33–44.PubMedCrossRef
33.
Oyinloye, B. E., Ajiboye, B. O., Ojo, O. A., Nwozo, S. O., & Kappo, A. P. (2016). Cardioprotective and antioxidant influence of aqueous extracts from Sesamum indicum seeds on oxidative stress induced by cadmium in Wistar rats. Pharmacognosy Magazine, 12(Suppl 2), S170–S174.PubMedPubMedCentral
34.
Priya, L. B., Baskaran, R., Elangovan, P., Dhivya, V., Huang, C. Y., & Padma, V. V. (2017). Tinospora cordifolia extract attenuates cadmium-induced biochemical and histological alterations in the heart of male Wistar rats. Biomedicine & Pharmacotherapy, 87, 280–287.CrossRef
35.
Jamall, I. S., & Smith, J. C. (1985). Effects of cadmium on glutathione peroxidase, superoxide dismutase, and lipid peroxidation in the rat heart: A possible mechanism of cadmium cardiotoxicity. Toxicolog and Applied Pharmacology, 80(1), 33–42.CrossRef
36.
Alpsoy, S., Kanter, M., Aktas, C., et al. (2014). Protective effects of onion extract on cadmium-induced oxidative stress, histological damage, and apoptosis in rat heart. Biological Trace Element Research, 159(1–3), 297–303.PubMedCrossRef
37.
Yao, Y., Zhao, X., Zheng, S., Wang, S., Liu, H., & Xu, S. (2021). Subacute cadmium exposure promotes M1 macrophage polarization through oxidative stress-evoked inflammatory response and induces porcine adrenal fibrosis. Toxicology, 461, 152899.PubMedCrossRef
38.
Xu, S., Xiaojing, L., Xinyue, S., Wei, C., Honggui, L., & Shiwen, X. (2021). Pig lung fibrosis is active in the subacute CdCl 2 exposure model and exerts cumulative toxicity through the M1/M2 imbalance. Ecotoxicology and Environmental Safety, 225, 112757.PubMedCrossRef
39.
Lubos, E., Loscalzo, J., & Handy, D. E. (2011). Glutathione peroxidase-1 in health and disease: From molecular mechanisms to therapeutic opportunities. Antioxidants & Redox Signaling, 15(7), 1957–1997.CrossRef
40.
Esworthy, R. S., Ho, Y. S., & Chu, F. F. (1997). The Gpx1 gene encodes mitochondrial glutathione peroxidase in the mouse liver. Archives of Biochemistry and Biophysics, 340, 59–63.PubMedCrossRef
41.
Esworthy, R. S., Yang, L., Frankel, P. H., & Chu, F. F. (2005). Epithelium-specific glutathione peroxidase, Gpx2, is involved in the prevention of intestinal inflammation in selenium-deficient mice. Journal of Nutrition, 135, 740–745.PubMedCrossRef
42.
Darwish, W. S., Chen, Z., Li, Y., Wu, Y., Chiba, H., & Hui, S. P. (2020). Identification of cadmium-produced lipid hydroperoxides, transcriptomic changes in antioxidant enzymes, xenobiotic transporters, and pro-inflammatory markers in human breast cancer cells (MCF7) and protection with fat-soluble vitamins. Environmental Science and Pollution Research, 27(2), 1978–1990.PubMedCrossRef
43.
Refaie, M. M. M., El-Hussieny, M., Bayoumi, A. M. A., & Shehata, S. (2019). Mechanisms mediating the cardioprotective effect of carvedilol in cadmium induced cardiotoxicity. Role of eNOS and HO1/Nrf2 pathway. Environmental Toxicology Pharmacology, 70, 103198.PubMedCrossRef
44.
Bashir, N., Shagirtha, K., Manoharan, V., & Miltonprabu, S. (2019). The molecular and biochemical insight view of grape seed proanthocyanidins in ameliorating cadmium-induced testes-toxicity in rat model: Implication of PI3K/Akt/Nrf-2 signaling. Bioscience Reports, 39(1), BSR20180515.PubMedPubMedCentralCrossRef
45.
Zhang, J., Sun, Z., Lin, N., et al. (2020). Fucoidan from Fucus vesiculosus attenuates doxorubicin-induced acute cardiotoxicity by regulating JAK2/STAT3-mediated apoptosis and autophagy. Biomedicine & Pharmacotherapy, 130, 110534.CrossRef
46.
Zhang, L., Liu, L., & Li, X. (2020). MiR-526b-3p mediates doxorubicin-induced cardiotoxicity by targeting STAT3 to inactivate VEGFA. Biomedicine & Pharmacotherapy, 123, 109751.CrossRef
47.
Pipicz, M., Demján, V., Sárközy, M., & Csont, T. (2018). Effects of cardiovascular risk factors on cardiac STAT3. International Journal of Molecular Sciences, 19(11), 3572.PubMedPubMedCentralCrossRef
48.
Chu, X., Zhang, Y., Xue, Y., et al. (2020). Crocin protects against cardiotoxicity induced by doxorubicin through TLR-2/NF-kappaB signal pathway in vivo and vitro. International Immunopharmacology, 84, 106548.PubMedCrossRef
49.
Kabel, A. M., & Elkhoely, A. A. (2017). Targeting proinflammatory cytokines, oxidative stress, TGF-beta1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. Biomedicine & Pharmacotherapy, 93, 17–26.CrossRef
50.
McIlwain, D. R., Berger, T., & Mak, T. W. (2013). Caspase functions in cell death and disease. Cold Spring Harbor Perspectives in Biology, 5(4), a008656.PubMedPubMedCentralCrossRef
51.
Kang, T. B., Ben-Moshe, T., Varfolomeev, E. E., Pewzner-Jung, Y., Yogev, N., Jurewicz, A., Waisman, A., Brenner, O., Haffner, R., Gustafsson, E., et al. (2004). Caspase-8 serves both apoptotic and nonapoptotic roles. Journal of Immunology, 173, 2976–2984.CrossRef
52.
Brenner, D., & Mak, T. W. (2009). Mitochondrial cell death effectors. Current Opinion in Cell Biology, 21, 871–877.PubMedCrossRef
53.
Chang, Y. K., Choi, H., Jeong, J. Y., et al. (2016). Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS ONE, 11(7), e0158810.PubMedPubMedCentralCrossRef
54.
Dekkers, C. C. J., Petrykiv, S., Laverman, G. D., Cherney, D. Z., Gansevoort, R. T., & Heerspink, H. J. L. (2018). Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes, Obesity and Metabolism, 20(8), 1988–1993.PubMedCrossRef
55.
Shibusawa, R., Yamada, E., Okada, S., et al. (2019). Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death. Scientific Reports, 9(1), 9887.PubMedPubMedCentralCrossRef
56.
Chang, W. T., Lin, Y. W., Ho, C. H., Chen, Z. C., Liu, P. Y., & Shih, J. Y. (2021). Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients. Archives of Toxicology, 95(2), 659–671.PubMedCrossRef
57.
Zhang, N., Feng, B., Ma, X., Sun, K., Xu, G., & Zhou, Y. (2019). Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovascular Diabetology, 18(1), 107.PubMedPubMedCentralCrossRef
58.
Lim, G. B. (2020). Dapagliflozin reduces left ventricular mass. Nature Reviews Cardiology, 17(9), 540.PubMed
59.
Garnock-Jones, K. P. (2017). Saxagliptin/dapagliflozin: A review in type 2 diabetes mellitus. Drugs, 77(3), 319–330.PubMedCrossRef
Metadata
Title
RETRACTED ARTICLE: Dapagliflozin Guards Against Cadmium-Induced Cardiotoxicity via Modulation of IL6/STAT3 and TLR2/TNFα Signaling Pathways
Authors
Marwa M. M. Refaie
Rehab Ahmed Rifaai
Michael Atef Fawzy
Sayed Shehata
Publication date
15-10-2022
Publisher
Springer US
Keyword
Dapagliflozin
Published in
Cardiovascular Toxicology / Issue 10-11/2022
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-022-09768-0

Other articles of this Issue 10-11/2022

Cardiovascular Toxicology 10-11/2022 Go to the issue

OriginalPaper

Protective Effect of Ginsenosides Rg1 on Ischemic Injury of Cardiomyocytes After Acute Myocardial Infarction

OriginalPaper

Alpha-Lipoic Acid Protects Against Doxorubicin-Induced Cardiotoxicity by Regulating Pyruvate Dehydrogenase Kinase 4

OriginalPaper

Genistein Alleviates Oxidative Stress and Inflammation in the Hypothalamic Paraventricular Nucleus by Activating the Sirt1/Nrf2 Pathway in High Salt-Induced Hypertension

BriefCommunication

PD-1 Inhibitor-Induced Thyrotoxicosis Associated with Coronary Artery Spasm and Ventricular Tachycardia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits